Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.05), $0.13 better than the analyst estimate of ($0.18).

Second Quarter 2016 and Recent Highlights

• Announced positive topline results from U.S. Phase 2 randomized, placebo controlled study of NurOwn in patients with ALS.
  • Study achieved its primary objective, demonstrating that NurOwn was safe and well tolerated.
  • NurOwn also achieved multiple secondary efficacy endpoints, showing clear evidence of a clinically meaningful benefit.
  • Response rates (based on ALSFRS-R responder analysis) were higher in NurOwn-treated subjects compared to placebo at all time points in the study out to 24 weeks.
  • Further evidence of biological effect was demonstrated by the increased levels of growth factors in the cerebrospinal fluid and decreased inflammatory markers observed after two weeks.
  • Results will be used to help determine the study population and design for a registration study investigating multiple doses of NurOwn in ALS.
  • Phase 2 study was conducted at three sites in the U.S: Massachusetts General Hospital, UMass Medical School and the Mayo Clinic.

• Company was awarded $1.5 million in non-dilutive funding from Israel's Office of the Chief Scientist.
• Mr. Chaim Lebovits, CEO, moderated a round table session on Brainstorm's NurOwn proprietary technology at the 11th World Stem Cells & Regenerative Medicine Congress in London, UK.

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.